AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.

A number of other research analysts have also issued reports on ACRX. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Roth Capital restated a “buy” rating and set a $12.50 target price on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 10th. Jefferies Group LLC restated a “buy” rating and set a $7.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, July 14th. Finally, Piper Jaffray Companies set a $3.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $7.50.

Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 3.33% on Friday, reaching $3.10. 1,116,705 shares of the company’s stock were exchanged. The company’s market cap is $140.68 million. The firm’s 50-day moving average price is $3.12 and its 200 day moving average price is $2.81. AcelRx Pharmaceuticals has a 12 month low of $1.95 and a 12 month high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.01). AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The business had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. Equities research analysts predict that AcelRx Pharmaceuticals will post ($1.13) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “AcelRx Pharmaceuticals, Inc. (ACRX) Lowered to Strong Sell at ValuEngine” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/15/acelrx-pharmaceuticals-inc-acrx-lowered-to-strong-sell-at-valuengine.html.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vincent J. Angotti purchased 15,000 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $3.00 per share, with a total value of $45,000.00. Following the purchase, the chief executive officer now directly owns 15,000 shares of the company’s stock, valued at approximately $45,000. The disclosure for this purchase can be found here. In the last three months, insiders purchased 37,000 shares of company stock valued at $112,280. 28.10% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC increased its position in shares of AcelRx Pharmaceuticals by 326.1% during the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares during the period. Teachers Advisors LLC increased its position in shares of AcelRx Pharmaceuticals by 14.6% during the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares during the period. Virtu KCG Holdings LLC increased its position in shares of AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares during the period. LMR Partners LLP acquired a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth $319,000. Finally, Bank of New York Mellon Corp increased its position in shares of AcelRx Pharmaceuticals by 6.6% during the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares during the period. Institutional investors own 23.32% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.